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Abstract: Hematopoietic development is orchestrated by gene regulatory networks that 
progressively induce lineage-specific transcriptional programs. To guarantee the 
appropriate level of complexity, flexibility, and robustness, these networks rely on 
transcriptional and post-transcriptional circuits involving both transcription factors (TFs) 
and microRNAs (miRNAs). The focus of this review is on RUNX1 (AML1), a master 
hematopoietic transcription factor which is at the center of miRNA circuits necessary for 
both embryonic and post-natal hematopoiesis. Interference with components of these 
circuits can perturb RUNX1-controlled coding and non-coding transcriptional programs  
in leukemia.  
Keywords: RUNX1 (AML1); microRNAs (miRNAs); hematopoiesis; leukemia; 
transcription factor-microRNA circuits; gene regulatory networks 
 
1. Introduction 
During embryonic and post-natal hematopoiesis, a limited pool of hematopoietic stem cells (HSCs) 
gives rise to all blood cell types through hierarchical specification of different hematopoietic lineages. 
Development, self-renewal, lineage commitment, and maturation of HSCs and multipotent progenitor 
cells are orchestrated by soluble growth factors and signals from the microenvironment, as well as  
cell-autonomous changes in gene expression. During hematopoietic differentiation, lineage-specific 
genes are progressively induced, while alternative-lineage genes are progressively silenced through 
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heritable chromatin changes. The regulation of these processes relies on a complex interplay between 
hematopoietic transcription factor networks and post-transcriptional regulators, in particular microRNAs 
(miRNAs). In this review, we specifically focus on RUNX1, a master hematopoietic transcription 
factor at the center of a miRNA network relevant for both normal and malignant hematopoiesis. 
2. Transcription Factor-MicroRNA Networks in Hematopoiesis 
Hematopoiesis starts during embryonic development and continues throughout life to guarantee 
proper generation and constant availability of blood cells (for general reviews see [1–3]).  
During embryonic development, hematopoiesis occurs in two waves. In the first wave, hematopoiesis 
(called primitive) takes place in the yolk sack and results in the transient production of primitive 
hematopoietic cells, mainly erythrocytes, necessary to support initial embryonic growth [1].  
These primitive cells are morphologically different from, and do not give rise to, adult hematopoietic 
cells. In the second wave, hematopoiesis (called definitive) occurs at multiple sites, and eventually 
gives rise to the adult hematopoietic system. During definitive hematopoiesis, a pool of hematopoietic 
stem cells (HSCs) is produced in both extra embryonic and embryonic regions derived from the 
mesoderm, such as the placenta and the aorta-gonad mesonephros (AGM) region [2]. In these regions,  
mesoderm-derived endothelial/blood precursors differentiate into a “hemogenic endothelium”, which 
undergoes an epithelial-hematopoietic transition whereby endothelial-like cells become non-adherent 
and acquire HSC features [2,4]. These HSCs later colonize the fetal liver and, ultimately, the bone 
marrow, where they sustain hematopoiesis throughout life. HSCs are capable of both self-renewal and 
generation of multipotent progenitor cells, which progressively become committed and produce 
distinct hematopoietic lineages [1,2].  
The different hematopoietic cell types are characterized by very specific gene expression  
profiles that reflect the progressive restriction of their differentiation potential [5]. Several transcription 
factors (TF) play a key role in determining the correct temporal activation or repression of  
specific hematopoietic transcriptional programs during both HSC establishment/maintenance and  
lineage-specific differentiation and function (for general reviews see [1,5,6]). For instance, the ETS 
transcription factor FLI1 is indispensable for the formation of the epithelial/blood precursors [7], 
SCL/TAL1 is required for their differentiation into the hemogenic endothelium [8,9], and RUNX1 is 
necessary for the formation of HSCs from the hemogenic endothelium [10–12]. Differentiation into 
more committed progenitors and mature blood cells involves also other TFs, including NFI-A, PU.1 
and CEBP family members, whose balance is critical to determine myeloid and lymphoid cell  
fates [13–21]. Interestingly, HSCs express not only TFs strictly required for their homeostasis and  
self-renewal, but also many others that characterize the development of multiple lineages [5].  
Thus, during lineage commitment it is not only necessary to activate the gene networks that identify a 
specific lineage, but also to repress the programs associated with alternate lineages [5]. It is becoming 
apparent that this level of complexity cannot be determined by single TFs, but instead relies on 
positive and negative regulatory interactions within TF networks [22,23] as well as TF-miRNAs 
circuits [24–26].  
The role of miRNAs in hematopoiesis is well established, and has been recently and amply 
reviewed [25–30]. One of the most remarkable properties of miRNAs is their ability to affect entire 
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cellular processes by controlling multiple targets of the same pathway [31]. In this respect, very small 
changes in miRNA expression are expected to have a cumulative effect and result in much greater 
biological outcomes. The reach of miRNA action is further extended by the interplay between  
miRNA-controlled networks and TF networks. Not only TFs and miRNAs frequently share the same 
targets, but some miRNAs often target TFs that modulate their own transcription. This interplay results 
in transcriptional/post-transcriptional feedback and feed-forward loops that both expand and fine-tune 
the action of single TFs/miRNAs [31]. TF-miRNA circuits not only are predicted by bioinformatics’ 
analyses [32,33], but are also supported by growing experimental evidence, particularly from 
hematopoietic models (reviewed by [25,34]). For instance, monocytic and granulocytic differentiation 
involves at least three such circuits [25]. In one circuit, CEBPA (CCAAT/enhancer-binding protein 
alpha) is induced by granulocyte colony stimulating factor during granulopoiesis and is part of a  
feed-forward loop whereby CEBPA positively modulates miR-223 and NFIA transcription, while 
miR-223 represses NFIA expression [35]. Repression of NFIA on one hand prevents the initiation of 
erythropoietic transcriptional programs, and on the other hand drives granulopoiesis [20,21]. In a 
second circuit, PU.1 induces both miR-424 and NFI-A, while miR-424 represses NFIA  
expression [36]. Both NFI-A downregulation by RNAi and miR-424 overexpression have been shown 
to promote monocytic differentiation [36]. In addition, as we will examine more in detail later in this 
review, monocytic differentiation involves a third circuit linking RUNX1 and the miR-17-92  
cluster [37].  
Establishing transcriptional and post-transcriptional feedback circuits gives cells, at the same time, 
sufficient flexibility to instruct specific differentiation programs, and the necessary robustness to 
maintain these programs throughout cell life [23]. It is not surprising that interference with any of the 
components of these complex circuits often leads to hematopoietic malignancies [38]. 
3. RUNX1 in Hematopoiesis and Leukemia 
3.1. RUNX1: A Master Regulator of Hematopoiesis 
RUNX1 (also known as AML1 and CBF alpha) plays an essential role both in the generation of 
definitive HSCs during embryonic development and in the maintenance of lineage differentiation 
during adult hematopoiesis (for general reviews see [39–42]). RUNX1 was originally identified in 
acute myeloid leukemia (AML) patients with t(8;21), where the fusion with the ETO gene impairs its 
function [43–46]. During mouse development, Runx1 is expressed in specific subsets of endothelial 
cells in all embryonic and extraembryonic hematopoietic sites, even before the emergence of definitive 
HSCs, thus suggesting a critical role in the hemogenic endothelium [11,42]. Indeed, homozygous 
Runx1 knock out in mice is embryonic lethal due to extensive hemorrhages (derived from primitive 
erythroblasts) and complete absence of definitive hematopoietic progenitors and HSCs in all 
hematopoietic sites [47,48]. Surprisingly, mice in which Runx1 was conditionally knocked out in 
endothelial cells, displayed the same hematopoietic deficiencies observed in non-conditional Runx1 
knockout mice, while mice with Runx1 conditional knock out in hematopoietic-committed cells still 
displayed definitive hematopoiesis [10]. This finding shows that Runx1 plays an essential role in the 
formation of HSCs from the hemogenic endothelium, but its expression is no longer necessary for 
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embryonic hematopoiesis once HSCs have been established. Nevertheless, Runx1 widespread 
expression in most adult hematopoietic lineages and HSCs suggests a role also in post-natal 
hematopoiesis [49,50]. According to a few studies, conditional Runx1 knockout in adult HSCs results 
in expansion of the Lin-Sca-c-Kit+ population (putative HSCs), but the same effect was not observed 
in other studies [10,51–54]. A more consistent phenotype associated with conditional Runx1 knockout 
in adult HSCs is the expansion of myeloid progenitors, which may be due to a partial block of myeloid 
differentiation [52,53]. Runx1 deficient adult mice also showed impaired lymphoid and megakaryocytic 
differentiation, a reduced number of lymphoid progenitors, and thrombocytopenia [52,53]. Overall, 
Runx1 seems to play a critical role as a differentiation inducer: first it is necessary for “differentiation” 
of endothelial cells into HSCs, then it reduces HSCs self-renewal and promotes differentiation of the 
myeloid, lymphoid and megakaryocytic lineages [39].  
RUNX1 function in hematopoiesis is determined by cell context-specific interactions with DNA, 
other TFs, and co-factors. The characterizing domain of RUNX1 is the N-terminal Runt homology 
domain (RHD), a conserved DNA binding domain necessary both for the recognition of the  
DNA consensus sequences 5'-PuACCPuCA-3' [55], and for binding to the co-factor CBF beta  
(CBFB) [56,57]. CBFB does not interact with DNA directly, but its binding strongly enhances 
RUNX1 DNA-binding affinity and is necessary for RUNX1 function [56–58]. The heterodimer formed 
by RUNX1 (also called CBF alpha) and CBFB is often referred to as a single functional unit, known as 
Core Binding Factor (CBF). Cbfb knock out in mice almost completely phenocopies Runx1 knock out, 
resulting in ablation of definitive hematopoiesis and embryonic lethality [58,59]. The C-terminus of 
RUNX1 contains regulatory regions that mediate the interaction with either transcriptional activators 
or transcriptional co-repressors [60–62]. By recruiting chromatin modifying enzymes such as the 
histone acetylases P300, CBP and MOZ [60,63], histone deacetylases (via the co-repressors Sin3A and 
Groucho/TLE) [64–66], or the Polycomb Repressive complex PRC1 [67], RUNX1 can locally modify 
the chromatin of specific target genes and either facilitate or impede their transcription. The occurrence 
of activation or repression is apparently determined by the cell context, the promoter context, the local 
interaction with other TFs and, possibly also by RUNX1 post-translational modifications [39,40,68,69]. 
During HSC formation, RUNX1 transcriptional activation seems to be the predominant function [42]. 
Indeed, a recent study shows that at the onset of definitive hematopoiesis, RUNX1 orchestrates global 
reorganization of lineage-specific TF assemblies with a concomitant increase in histone acetylation at 
specific regulatory elements [70].  
A number of direct target genes have been described to be regulated by RUNX1, both in 
hematopoietic stem cells/precursors and more mature blood cells. For instance, RUNX1 directly binds 
and activates PU.1 and CEBPA, two transcription factors critical for determination of the myeloid and 
lymphoid lineage from hematopoietic precursors [71,72]. In more committed cells, RUNX1 directly 
modulates the expression of multiple lineage-specific genes, including myeloid-specific growth factor 
signaling genes such as IL-3, GM-CSF, M-CSF receptor (CSF1R), and genes relevant for myeloid 
function, such as MPO [73–76]. In addition, as we will discuss later in this review, RUNX1 regulates 
microRNAs involved in the development of different lineages. 
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3.2. RUNX1 Perturbations in Leukemia 
RUNX1 and CBFB are frequent targets of chromosomal abnormalities in hematopoietic 
malignancies, particularly in leukemia (also referred to as CBF leukemia or CBFL). RUNX1 is one of 
the most common targets of chromosomal translocations in acute leukemia [40]. Over 50 chromosome 
translocations affecting the RUNX1 gene on chromosome 21 and over 20 different partner genes have 
been described [40,77,78]. One of the most recurrent translocations involving RUNX1 is the t(8;21), 
which is found in 30%–40% of acute myeloid leukemia (AML) FAB-M2 [40,77]. The t(8;21) 
juxtaposes part of the RUNX1 gene with part of the ETO (MTG8/RUNX1T1) gene on chromosome 8, 
and results in the production of the chimeric protein RUNX1-ETO (AML1-ETO/AML1-MTG8/ 
RUNX1-RUNX1T1) [43–46]. This fusion protein retains the N-terminal, DNA-binding RHD domain 
of RUNX1, but loses the C-terminal regulatory regions of RUNX1, which are replaced by the  
C-terminal functional domains of the ETO protein. ETO belongs to the MTG family of  
transcriptional co-repressors and contains four conserved domains (NHR regions) that mediate 
homo/heterodimerization with other MTG proteins as well as interaction with histone deacetylases or 
other co-repressors [79]. Interestingly, another member of the MTG family, MTG16, is also found 
fused to RUNX1 in AML with t(16;21) translocation, and the resulting fusion protein RUNX1-MTG16 
(AML1-MTG16) shares most of the molecular features of RUNX1-ETO [79,80].  
Several studies indicate that RUNX1-MTG fusion proteins act in part as dominant negatives over 
wild type RUNX1, as they competitively bind to RUNX1 consensus sequences of the same target 
genes, but they also bring about the repressive activities of the MTG moiety [81–84]. Indeed,  
RUNX1-MTG proteins induce repressive chromatin changes at both DNA and histone levels in the 
regulatory regions of many myeloid genes typically activated by RUNX1, including CSF1R, p14ARF, 
and p21CIP1 [85–88]. However, it has been reported that RUNX1-ETO can also upregulate the 
expression of some RUNX1-targets [89,90] as well as bind preferentially regions with duplicated 
RUNX1 consensus sequences [91], suggesting that the effects of this fusion protein may involve a gain 
of function in addition to the loss of RUNX1 function. Mouse models indeed support this hypothesis. 
Early RUNX1-ETO knock-in mouse models were embryonic lethal and recapitulated many, but not 
all, of the phenotypes observed in Runx1 KO mice [92,93]. Subsequent transgenic models in which 
RUNX1-ETO was expressed only in adult bone marrow overcame embryonic lethality, and showed an 
increased number of granulocyte/macrophage progenitors [94]. This phenotype was similar to the one 
observed in Runx1 conditional knockout mice, but no lymphocytopenia or thrombocytopenia was 
observed [94]. Common to all RUNX1-ETO animal models developed so far is the inability of the 
fusion protein to induce overt leukemia [94–96], unless additional mutations are present [97]. In line 
with these findings is the observation that up to 50% of pediatric patients with t(8;21) display the 
translocation already at birth, but overt leukemia occurs only years later [98]. Apparently, t(8;21) cells 
remain in a “pre-leukemic” state until additional hits trigger leukemic growth. 
Similarly to RUNX1, CBFB is also a target of chromosome rearrangements in leukemia. 
Approximately 3%–10% of AML cases are characterized by inv(16) [38], which leads to the fusion of 
the CBFB gene with MYH11 (coding for the smooth muscle heavy chain) and the consequent 
production of the chimeric protein CBFB-MYH11 [99,100]. Like AML1-ETO, although through a 
different mechanism, CBFB-MYH11 acts as a dominant negative of the wild type RUNX1/CBFB 
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complex and leads to deregulation of RUNX1-target genes [101]. Non-conditional transgenic 
expression of CBFB-MYH11 in mice results in embryonic lethality with a phenotype similar to 
Runx1/Cbfb knockout mice [102], while conditional expression in the bone marrow results in an 
increase of the HSC population and abnormal myeloid progenitors [103]. Differently from  
AML1-ETO, expression of CBFB-MYH11 seems sufficient to generate AML [103]. 
A significant number of AML cases without karyotypic abnormalities involving RUNX1 or CBFB 
can still have an impaired CBF function, due to other factors such as point mutations, deletions, or 
simply transcriptional or post-transcriptional downregulation. The identification of inherited  
mono-allelic RUNX1 intragenic deletions in familial platelet disorder (FPD), which is associated with 
a higher risk to develop AML, points to RUNX1 haploinsufficiency, and not only RUNX1 
translocations, as a leukemia pre-disposing factor [104]. More recent large-scale sequencing studies 
have uncovered the occurrence of RUNX1 mutations in a significant percentage of AML and 
myelodysplastic syndrome (MDS) [105–107]. The most frequent mutations occur in the RUNX1 RHD 
domain and result in loss of the protein function [108]. It is interesting to note that different mutations 
can result in different biological effects, which sometimes show gain of function relatively to the 
simple loss of RUNX1 [39,109]. Although RUNX1 mutations do not seem to be sufficient to trigger 
leukemia [39], many of them are associated with poor outcome [110]. It has been estimated that the 
combination of RUNX1 mutations and chromosome rearrangements affecting RUNX1/CBFB may 
account for approximately 28% of all adult AML cases [108]. The dramatic biological consequences of 
RUNX1 hypomorphic mutations or monoallelic loss [111] indicate that RUNX1 dosage is indeed 
critical for normal hematopoiesis.  
4. RUNX1: A MicroRNA Hub in Normal and Malignant Hematopoiesis  
4.1. MicroRNAs Targeting RUNX1 
RUNX1 is part of TF-miRNA circuits that guarantee a robust transcriptional and  
post-transcriptional control of its expression during hematopoiesis. RUNX1 expression is not only 
modulated by key hematopoietic TFs, such as GATA2, ETS factors, SCL [112] and by RUNX1  
itself [113], but also by an expanding number of miRNAs. Basic in silico analyses with bioinformatics 
tools (e.g., TargetScan) predict over 60 conserved miRNAs targeting the longest RUNX1 3'UTR, 
many of which have been validated [37,114,115] (Figure 1). In particular, the miR-17-92 cluster and 
miR-27 seem to play an important role in regulating RUNX1 protein dosage and, consequently, 
RUNX1 function in hematopoietic differentiation. 
The miR-17-92 cluster is transcribed into six distinct miRNAs, which include miR-17 and  
miR-20a [116]. MiR17-92 promotes cell proliferation and survival by targeting key tumor suppressors, 
such as p21CIP21 and PTEN [117,118], and is one of the first miRNAs with a validated oncogenic 
activity [119]. Indeed, miR-17 is frequently overexpressed in cancer, including lymphoma and 
leukemia [119–123]. Fontana et al. have shown that miR-17, miR-20a, and the highly homologous 
miR-106a, are expressed at high levels in early myeloid progenitors, but are downregulated during 
monocytic differentiation of human CD34+ cells [37]. All three miRNAs target conserved sites in the 
RUNX1 3'UTR, and their downregulation results in increased RUNX1 levels. RUNX1 upregulation, in 
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turn, leads to increased transcription of its direct target gene for the macrophage colony stimulating 
factor receptor, CSF1R, which promotes macrophage differentiation [37]. Remarkably, the miR-17 and 
the miR-106 clusters contain RUNX1 consensus sequences in their promoter regions, and their 
transcription can be directly repressed by RUNX1 through a mutual negative feedback loop. This 
reciprocal inhibitory mechanism facilitates the switch from an undifferentiated state, in which high 
miR-17-106 levels maintain low levels of RUNX1 and CSF1R, to a differentiated state, where  
miR-17-106 levels decrease to allow RUNX1-mediated CSF1R upregulation [37] (Figure 1).  
Figure 1. (a) RUNX1 is a hub of miRNAs targeting RUNX1 and miRNAs targeted by 
RUNX1. A number of miRNAs (>60 predicted by Targetscan, of which shown are only the 
ones experimentally validated) can inhibit RUNX1 protein expression by targeting the 
3’UTR of RUNX1 mRNA. RUNX1 is predicted to target more than 200 miRNAs  
(shown are only the ones experimentally validated) and either repress or activate their 
transcription. Some miRNAs, such as miR-17 and miR-27, in turn can target RUNX1 in a 
feedback loop (dotted arrow). (b) Examples of possible RUNX1-miRNA feedback loops 
involved in megakaryocytic, monocytic, and granulocytic differentiation. In the latter case, 
RUNX1 may control miR-27 transcription indirectly, via CCAAT/enhancer-binding 
protein alpha (CEBPA) (dotted arrow). 
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MiR-27 was identified as a candidate RUNX1-targeting miRNA through miRNA prediction 
algorithms, and further validated experimentally by two independent groups [114,115]. Ben-Ami et al. 
showed that miR-27a binds the 3'UTR of RUNX1, attenuating its expression [114]. Since miR-27a is 
transcriptionally regulated by RUNX1 in a feedback loop, the authors postulate that the upregulation of 
RUNX1 in the early hematopoietic stages positively regulates miR-27a to attenuate RUNX1 level 
during megakaryopoiesis. Interestingly, miR-27a increases upon induction of megakaryocytic 
differentiation of K562 cells, while it decreases during erythroid differentiation, suggesting a role in 
the determination of the erythroid/megakaryocytic lineages from the common precursor [114] (Figure 1). 
In addition, Feng et al. reported that miR-27 also plays a role in granulocytic differentiation [115]. 
During CSF3 (granulocyte colony stimulating factor)-induced granulocytic differentiation of 32D.cl3 
cells, miR-27 is upregulated concomitantly with RUNX1 downregulation. Gain- and loss-of-function 
experiments showed that indeed miR-27 directly controls RUNX1 levels and affects granulocyte 
differentiation [115]. RUNX1 acts as a repressor of the CSF3 receptor (CSF3R) [90], and its 
downregulation by miR-27 would promote granulocytic differentiation by preventing RUNX1-mediated 
CSF3R repression. In this cell model, RUNX1 may not affect miR-27 level directly, but through 
regulation of CEBPA, a RUNX1-target TF that induces miR-27 transcription (Figure 1). 
MicroRNA-mediated RUNX1 control can be modulated at multiple levels. First, miRNA action can 
be influenced by alternative splicing of the RUNX1 3'UTR. The RUNX1 gene encodes at least three 
splice variants, characterized by 3’UTRs that differ both in sequence and size. Splice variant 1 and 2 
(AML1c and AML1b, respectively) share the same 3'UTR (over 4000 bp) and encode the longest 
RUNX1 protein isoforms, with similar structure and function. Splice variant 3 (AML1a) contains a 
very short 3'UTR (less than 400 bp) with a different sequence from the 3’UTR of the longer isoforms. 
This variant encodes for the shortest RUNX1 protein isoform, which lacks most of the longer RUNX1 
functional domains. Since the long and short RUNX1 isoforms seem to have antagonistic effects on 
myeloid differentiation and proliferation [124], miRNAs could produce diverse biological responses 
by differentially regulating the level of the various RUNX1 isoforms. For instance, while miR-27 can 
target the 3'UTR of both short and long isoforms, even if with different repressive strength, miR-17 
can target only the 3'UTR of the longer RUNX1 isoforms [114,115]. In addition, miRNA can affect 
RUNX1 dosage indirectly, by targeting TFs controlling RUNX1 transcription. This seems to be the 
case of miR-27, which targets GATA2 through a feedback loop [112,114]. Moreover, since RUNX1 
can modulate its own transcription [113], miRNA-mediated RUNX1 post-transcriptional regulation 
could directly impact RUNX1 transcriptional control.  
4.2. MicroRNAs Targeted by RUNX1 
As we previously mentioned, RUNX1 directly modulates the transcription of entire coding gene 
networks through the recruitment of chromatin modifying enzymes. It has become more and more 
apparent that RUNX1 can similarly control miRNA genes endowed with RUNX1-consensus 
sequences in their regulatory regions. In two recent studies, RUNX1 occupancy was analyzed by 
ChIP-seq in different hematopoietic cells contexts [125,126]. A more in depth analysis of these  
ChIP-seq data reveals that a remarkable number (over 200 when two data sets are combined) of 
miRNA genes is physically bound by RUNX1. These studies suggest that RUNX1 regulates not only 
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coding-gene networks, but also miRNA networks. Indeed, several RUNX1-target miRNAs have been 
identified and validated. These include the above mentioned miR-17 and miR-27, which are part of 
RUNX1-miRNA regulatory loops, as well as other miRNAs involved in hematopoietic differentiation 
and proliferation (Figure 1).  
The first RUNX1-target miRNA, miR-223, was identified due to its deregulation by the  
RUNX1-ETO fusion protein [127]. In myeloid precursors, RUNX1 occupies a RUNX1-binding site in 
the miR-223 promoter and keeps the chromatin in a transcriptionally active state; in t(8;21)-positive 
cells, RUNX1-ETO competes with wild type RUNX1 for the miR-223 RUNX1-binding site and 
induces repressive chromatin modifications that silence the gene [127]. MiR-223 targets a number of 
genes critical for granulocyte function and development. Mutant mice lacking miR-223 display an 
increased number of granulocyte precursors, a phenotype that can be traced to the upregulation of the 
miR-223-target Mef2c, a transcription factor that promotes myeloid progenitor proliferation [128].  
In addition, miR-223 is part of at least two TF-miRNA circuits that play a key role in granolupoiesis: 
the miR-223-CEBPA-NFIA circuit that we have previously mentioned [35], and a feedback loop 
involving the transcription factor E2F1 [129]. E2F1 is a miR-223 target that inhibits granulopoiesis 
and induces myeloid cell cycle progression [129]. Induction of miR-223 results in downregulation of 
E2F1, thus leading to inhibition of cell cycle progression followed by myeloid differentiation. Since 
E2F1 represses miR-223 transcription, its downregulation concurs to increase miR-223 levels in a  
self-reinforcing loop [129]. 
We recently found that RUNX1 is also a direct transcriptional regulator of the miR-222-221 cluster. 
MiR-221 and miR-222 are highly homologous and target, among others, the tyrosine kinase receptor 
KIT [130]. Upon binding to its ligand, the stem cell factor (SCF), KIT activates downstream  
signaling pathways involved in survival, proliferation, and differentiation [131]. KIT plays a key  
role in maintaining self-renewal of hematopoietic stem cells at all developmental stages [132].  
During erythropoiesis, miR-222-221 expression declines, and leads to increased KIT protein levels and 
expansion of early erythropoietic cells [130]. Remarkably, KIT is often overexpressed in CBF 
leukemia concomitantly with miR-222-221 downregulation [133], suggesting that miR-222-221 may 
be under the transcriptional control of CBF (i.e., RUNX1 and CBFB). Indeed RUNX1 binds to a 
conserved consensus sequence in the miR-222-221 promoter and induces its transcriptional  
activation [133]. Interestingly, KIT appears to be targeted also by miR-193 [134,135] and  
miR-494 [136], both of which contain RUNX1 consensus sequences in their promoter regions 
(unpublished observations). 
RUNX1 targets also other miRNAs involved in hematopoietic proliferation and differentiation.  
For instance, RUNX1 donwregulates miR-181 [137], which seems to function as a molecular switch 
during hematopoietic lineage progression [138]. MiR-181 promotes megakaryocytic differentiation 
through repression of Lin28, and its inhibition has been shown to retard megakaryocytic differentiation 
in K562 cells [138]. Similarly, RUNX1 downregulates miR-24 [137], which plays a role in myeloid 
differentiation. MiR24 functions, at least in part, by downregulating MKP-7, a negative regulator of 
MAPK signaling. Consistently, miR-24 overexpression in myeloid progenitors results in a 
hyperproliferative phenotype and block of granulocytic differentiation [137]. MiR-24 is part of the 
miR-24-23-27 cluster, and RUNX1 directly interacts with consensus sequences in the promoter region 
of this cluster, repressing the transcription of the miR-24-23-27 pri-miRNA [137]. However, in another 
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study, RUNX1 binding to consensus sequences in the miR-27 locus was instead associated with  
miR-27 upregulation [114]. Further studies are needed to clearly dissect how RUNX1 regulates  
pri-miRNA transcription as well as the level of the single miRNAs derived from this cluster. 
Considering the number of miRNAs containing RUNX1-consensus sequences [125,126], it is likely 
that RUNX1 positively or negatively modulates the transcription of many other target miRNAs.  
Moreover, RUNX1-target transcription factors, such as CEBPA and PU.1, can also modulate the 
transcription of several other miRNAs relevant to hematopoiesis [139–142]. Thus, the range of 
RUNX1-mediated miRNA regulation could extend even further by encompassing not only direct 
miRNA targets, but also indirect miRNA targets via RUNX1-regulated TFs. 
4.3. Deregulation of RUNX1-Related miRNAs in Leukemia  
Both coding and miRNA genes transcriptionally controlled by RUNX1 are frequently deregulated 
in leukemia due to perturbation of RUNX1 function. As we briefly anticipated earlier in this review, 
the RUNX1-ETO fusion protein generated in t(8;21)-positive AML directly downregulates miR-223 
through recruitment of histone deacetylases (HDACs) and DNA methyl transferases (DNMTs), which 
impose repressive chromatin changes in the miR-223 promoter [127]. MiR-223 downregulation is 
common in t(8;21) patients, and may directly contribute to leukemogenesis by preventing granulocyte 
differentiation and promoting myeloid progenitor proliferation [127,128]. Similarly, we found that 
RUNX1-MTG fusion proteins can directly repress miR-222-221 transcription through direct binding to 
conserved RUNX1 consensus sequences in the miR-222-221 promoter [133]. Consistently, this 
miRNA cluster is frequently downregulated in CBF leukemia patients, concomitantly with the 
upregulation of its target KIT [133]. Upregulation of KIT, in turn, confers to t(8;21) cells a 
proliferative advantage, thus facilitating the transition from a pre-leukemic state to overt leukemia. 
Through analogous mechanisms, CBF fusion proteins are expected to deregulate the expression of 
many other RUNX1-target miRNAs. For instance, close inspection of published miRNA profiling 
datasets shows that miR-181, which is downregulated by wild type RUNX1, is consistently 
upregulated in t(8;21) AML samples [120,137,143]. In addition, both miR-24 and miR-27 have been 
found upregulated in CBF leukemia samples [120,137], while miR-17 and miR-20a seem to be mostly  
downregulated [123,143]. Deregulation of RUNX1-target miRNAs, however, is often observed also in 
non-CBF leukemia samples, indicating that these miRNAs can be targeted by other TFs, and/or that 
factors other than cytogenetic abnormalities can affect RUNX1 function or expression.  
It is likely that other factors in addition to chromosome rearrangements can affect RUNX1-target 
miRNAs. In this respect, it is particularly intriguing that deregulation of miRNA targeting RUNX1 
may result in deregulation of miRNA targeted by RUNX1. Since some of these miRNAs act in 
feedback loops, the deregulation of RUNX1 could either reinforce or counteract itself according to the 
nature of the loop (positive or negative feedback). For example, miR-17 upregulation, frequent in 
MLL-rearranged acute leukemia [123], would reduce RUNX1 levels and result in decreased  
RUNX1-mediated miR-17 transcriptional repression. This feedback loop would reinforce miR-17 
upregulation and further impair RUNX1 expression. In contrast, overexpression of miR-27, by 
decreasing RUNX1, would lead to its own transcriptional downregulation. It is of note that miRNAs 
can affect RUNX1 function also by targeting CBFB. A notable example is miR-125b, which plays an 
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important role in granulocyte differentiation and is often deregulated in hematopoietic  
malignancies ([144,145]). In addition, in silico analyses predict that many miRNAs (e.g., miR-27) can 
concomitantly target RUNX1 and CBFB, and that some RUNX1-target miRNAs (e.g., miR-222-221) 
could affect their own transcription by targeting CBFB (Figure 2). 
Figure 2. Several factors can potentially disrupt RUNX1-miRNA circuits, including 
deregulation of RUNX1-targeting miRNAs. RUNX1 function has been shown to be 
deregulated by altered RUNX1 dosage (haploinsufficiency), point mutations, or 
chromosomal rearrangements (e.g., t(8;21), producing RUNX1-ETO). In addition, RUNX1 
expression could be affected by deregulation of miRNAs targeting RUNX1.  
The impairment of RUNX1 function would lead to deregulation of RUNX1-target genes, 
including miRNAs (in red are shown the RUNX1-target miRNAs known to be repressed 
by RUNX1-ETO, while in black are shown other established RUNX1-target miRNAs). 
Deregulation of miR-223 and miR-222-221 by RUNX1-ETO is known to affect their 
targets, NF1A and KIT. Since RUNX1 can target, and be targeted by, the same miRNAs, 
deregulation of wild type RUNX1 may be reinforced or weakened through a feedback loop 
(dotted arrow). Similarly, RUNX1 function could be affected by impairment of its 
heterodimeric partner CBFB, which could be subjected to miRNA-mediated deregulation 
in addition to known chromosomal rearrangements. 
 
MiRNA-based deregulation of RUNX1 expression could explain why non-CBF leukemias are often 
characterized by molecular defects, such as KIT upregulation, typically produced by CBF karyotypic 
abnormalities. However, decreasing RUNX1 expression may not necessarily recapitulate all the 
molecular and biological effects of CBF fusion proteins. Indeed, CBF fusion proteins not only act as 
RUNX1 dominant negatives, but display also gain of function properties, which could be due, for 
instance, to a different subcellular localization [137], or preferential binding to specific consensus 
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sequences [91]. In addition, since miRNA action can differentially affect RUNX1 isoforms depending 
on their 3'UTR, miRNA deregulation could yield different biological effects according to the RUNX1 
isoforms targeted. It is also interesting to note that the loss of the RUNX1 3'UTR in some RUNX1 
fusion genes (e.g., RUNX1-ETO), and not in others (e.g., TEL-RUNX1), should differentially affect 
their post-transcriptional regulation by RUNX1-targeting miRNAs, and could contribute to define their 
oncogenic function. 
5. Concluding Remarks 
Gene regulatory networks (GRNs) have evolved in different organisms to guarantee the appropriate 
level of complexity, flexibility, and robustness necessary for development and cellular  
homeostasis [23]. GRNs typically have a modular and hierarchical structure, in which conserved 
smaller networks, or sub-circuits, with a given molecular/cellular function are combined to orchestrate 
cell fate [23]. Some of the best examples of these sub-circuits are represented by hematopoietic  
TF-miRNA circuits, such as the one centered on RUNX1. RUNX1 is part of circuits involving both 
RUNX1-targeting and RUNX1-targeted miRNAs. The involvement of RUNX1 in different stages of 
hematopoiesis suggests that RUNX1-based miRNA-TF circuits represent basic modules in 
developmental GRNs, and that these modules have the necessary versatility to be combined with other 
modules to direct the differentiation of distinct hematopoietic lineages. The centrality of RUNX1 
circuits in hematopoiesis is further supported by the dramatic biological effects consequent to RUNX1 
perturbation in hematopoietic malignancies (e.g., leukemia). 
RUNX1-centered regulatory circuits may not be restricted to hematopoiesis. A growing number of 
studies report that RUNX1 is deregulated also in solid tumors, suggesting that RUNX1 may play a role 
in development/homeostasis of non-hematopoietic tissues [146–149]. In particular, RUNX1 seems to 
play an important role in breast acinar morphogenesis [150], and is frequently downregulated or 
mutated in breast cancer [149,151–154]. The role of RUNX1 in breast acinar development may be 
linked to estrogen receptor alpha (ERA) signaling. A recent genome-wide analysis has shown that 
prior to estradiol stimulation, RUNX1 is present at many ERA-binding sites to keep the chromatin in a 
permissive state for subsequent ERA recruitment [155]. Interestingly, miR-222-221 is activated by 
RUNX1 and repressed by ERA [133,156], suggesting an intertwined mechanism involving ERA, 
RUNX1, and specific miRNAs in breast cells.  
In summary, RUNX1 seems to be a relevant hub of miRNA-regulated cell-specific circuits with 
diverse roles in multiple aspects of differentiation and development. Thus, deregulation of  
RUNX1-miRNA circuits is expected to be critical not only in the pathogenesis of leukemia, but also of  
other malignancies. 
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